Incannex Healthcare (ASX: IHL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Incannex Healthcare Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Incannex Healthcare (ASX: IHL)
Latest News
![A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera](https://www.fool.com.au/wp-content/uploads/2022/01/cannabis-field-16_9-400x225.jpg)
Cannabis Shares
Could ASX cannabis shares be set for a resurgence?
![Researchers working with medical cannabis.](https://www.fool.com.au/wp-content/uploads/2022/01/medical-cannabis-3-16.9-400x225.jpg)
Healthcare Shares
Incannex share price races higher on 'pivotal' trial approval
![a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.](https://www.fool.com.au/wp-content/uploads/2022/02/concern-400x225.jpg)
Share Fallers
Why Incannex, Magellan, Nexted, and Strandline shares are dropping today
![Man sitting in a plane seat works on his laptop.](https://www.fool.com.au/wp-content/uploads/2021/11/plane-16_9-400x225.jpg)
Healthcare Shares
Why you soon won't be able to find Incannex shares on the ASX
![two men in formal business clothing closely inspect a bud from a cannabis crop.](https://www.fool.com.au/wp-content/uploads/2021/10/GettyImages-1341005878-1-400x225.jpg)
Cannabis Shares
Why ASX cannabis shares just jumped back into the spotlight
![A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.](https://www.fool.com.au/wp-content/uploads/2022/10/manbun-400x225.jpg)
Cannabis Shares
Should I buy Incannex shares while they're at multi-year lows, or steer clear?
![Man in the green house growing medical cannabis](https://www.fool.com.au/wp-content/uploads/2021/08/Cannabis-in-the-green-house-16_9-400x225.jpg)
Cannabis Shares
A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why
![Man pointing at a blue rising share price graph.](https://www.fool.com.au/wp-content/uploads/2022/02/up-2-16.9-2-400x225.jpg)
Share Gainers
2 ASX All Ordinaries stocks leaping higher following strong quarters
![A cool white-bearded man holds his hand up signalling you should halt.](https://www.fool.com.au/wp-content/uploads/2021/09/Halt-that-trading-says-bearded-man-16_9-400x225.jpg)
Healthcare Shares
ASX 300 cannabis stock Incannex suspended ahead of 'material update'
![An older farmer wearing a checkered shirt and a straw hat stands in a green field of cannabis plants growing up to waist level as he smiles while thinking about the outlook for ASX cannabis shares in FY23](https://www.fool.com.au/wp-content/uploads/2021/10/GettyImages-1251447817-1-400x225.jpg)
Cannabis Shares
Buying ASX cannabis stocks? Here's what the Victorian government is considering right now
![A graphic showing a rising share price in medical cannabis shares](https://www.fool.com.au/wp-content/uploads/2021/04/cannabis-1-400x225.jpg)
Cannabis Shares
Why did this ASX 300 cannabis share just rocket 12%?
![A young female ASX investor sits at her desk with her fists raised in excitement as she reads about rising ASX share prices on her laptop.](https://www.fool.com.au/wp-content/uploads/2022/02/thrilled-16.9-1-400x225.jpg)
Share Gainers
2 ASX All Ords shares going gangbusters on Monday
Frequently Asked Questions
-
Incannex listed on the ASX in May 2007.
-
No, Incannex has not yet paid out any dividends.
IHL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Incannex Healthcare
Incannex Healthcare Ltd (ASX: IHL) is a developer of cannabinoid and psychedelic compound medicines. It is currently involved in clinical programs for the treatment of six conditions: Obstructive Sleep Apnea (OSA), Generalised Anxiety Disorder (GAD), traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions.
The company has an Australian license to import, export, and distribute medicinal cannabis products and has a line of cannabinoid products.
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
31 Oct 2023 | Peter Widdows | Buy | 280,000 | $18,545 |
On-market trade.
|
31 Oct 2023 | Peter Widdows | Buy | 230,954 | $15,296 |
On-market trade. As per announcement on 07-11-2023
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Troy Robert Valentine | Non-Executive ChairmanNon-Executive Director | Dec 2017 |
Troy Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartley s Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
|
Mr Peter Widdows | Non-Executive Director | Mar 2018 |
Mr Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartleys Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
|
Mr Joel Bradley Latham | Chief Executive OfficerExecutive DirectorManaging Director | Jul 2018 |
Joel Latham is the CEO and Managing Director of Incannex Healthcare and is responsible for the Companys commercial operations, strategic decision- making, and oversight of all clinical development assets. Joel has over 15 years commercial management and executive experience, working for a range multi-national publicly traded companies.
|
Dr George Anastassov | Non-Executive Director | Jun 2022 |
Dr Anastassov is responsible for APIRx commercial operations, strategic decision-making, and oversight of all clinical development assets. He is one of the developers of the first-in-the world cannabinoid-containing chewing gum-based delivery system among a number of other systems and formulations. Previously, he was CEO and co-founder of AXIM Biotechnologies, which achieved an all-time-high market capitalization of approximately US$1.2B.
|
Mr Lekhram Changoer | Non-Executive Director | Jun 2022 |
--
|
Mr Robert Bruce Clark | Non-Executive Director | Aug 2022 |
Mr Clark is a senior-level strategic regulatory affairs expert with over 38 years of US and Global regulatory experience, including >20 years with Pfizer Inc. and >10 years with Novo Nordisk A/S. He is an internationally recognized expert on US Food and Drug Administration ('FDA') and the European Medicines Agency (EMA) liaison interactions, US pharmaceutical advertising practices and regulatory aspects related to healthcare professionals and sales force activities. Mr Clark is Vice President, US Regulatory Affairsfor Novo Nordisk where he provides strategic leadership to a team of over 50 regulatory staff and scientists in the development of new medicines. He advises the global executive team on matters related to drug development programs, FDA liaison strategies, managing FDA-related compliance issues, and monitoring emerging US regulatory trends and opportunities.
|
Mr Madhukar (Madhu) Bhalla | Company Secretary | Jul 2021 |
-
|
Madhukar (Madhu) Bhalla | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 82,707,741 | 5.23% |
George Anastassov | 66,972,077 | 4.23% |
Prasch Bv | 63,954,841 | 4.04% |
Dr Sudhanshu Agarwal | 34,080,364 | 2.15% |
Cannvalate Pty Ltd | 32,000,000 | 2.02% |
Mr Raymond Laurence Carroll | 30,250,000 | 1.91% |
J P Morgan Nominees Australia Pty Limited | 23,906,440 | 1.51% |
Brownarrows Pty Ltd <Ejm A/C> | 23,610,000 | 1.49% |
BNP Paribas Noms Pty Ltd Deutsche Bank Tca <Drp> | 22,880,950 | 1.45% |
Citicorp Nominees Pty Limited | 19,087,124 | 1.21% |
Mr Peter Widdows | 15,973,694 | 1.01% |
Mr Kaide Wang | 15,700,000 | 0.99% |
IMI LLC | 14,642,234 | 0.93% |
Bagbo Pty Ltd | 14,516,434 | 0.92% |
Mr Brian Peter Byass | 14,247,191 | 0.90% |
Mr Joel Bradley Latham | 13,829,129 | 0.87% |
Gemini Capitall Llc <The Ars A/C> | 13,787,086 | 0.87% |
Slade Technologies Pty Ltd <Embrey Family S/F A/C> | 13,350,000 | 0.84% |
Alignment Capital Pty Ltd | 13,194,248 | 0.83% |
Ryba Llc | 13,090,170 | 0.83% |